Social anxiety disorder

Healis Therapeutics announces collaboration with Massachusetts General Hospital (MGH) and affiliates of Harvard Medical School to advance clinical-stage neuroscience research

Retrieved on: 
Tuesday, March 26, 2024
MGH, Harvard Medical School, Public health, Mass General Brigham, Massachusetts General Hospital, MDD, Patient, Public, Roche, Research, Merck, Social anxiety disorder, DSM-IV codes, Bristol Myers Squibb, Clinical trial, Neuropsychiatry, HMS, World Health Organization, Therapy, Hospital, Safety, WHO, SAD, Major depressive disorder, PTSD, Mass, Pharmaceutical industry

Healis Therapeutics is pleased to announce that it has entered a clinical collaboration with Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham health system, and affiliates of Harvard Medical School (HMS).

Key Points: 
  • Healis Therapeutics is pleased to announce that it has entered a clinical collaboration with Massachusetts General Hospital (MGH), a founding member of the Mass General Brigham health system, and affiliates of Harvard Medical School (HMS).
  • “We continue to observe very significant need in the neuropsychiatric patient population,” said Dr. Eric Finzi, Co-Founder of Healis Therapeutics.
  • “MDD remains a public health challenge around the world,” said Erik Van Widenfelt, Head of Clinical Trials at Healis Therapeutics.
  • General Hospital (MGH) and Harvard Medical School,” said Sebastian De Beurs, Co-Founder of Healis Therapeutics.

Tetricus Labs Partners with Silver Hill Hospital on Research to Advance Precision Psychiatry

Retrieved on: 
Tuesday, April 9, 2024
Data Management, Technology, Other Health, Health, Neurology, Mental Health, Research, Software, Artificial Intelligence, Hospitals, Science, Dow, Panic disorder, Psychiatry, Data science, Associate, Silver, Partnership, Patient, Tetricus, Bipolar disorder, Radiology, Neuroscience, Doctor of Philosophy, DSM-IV codes, Evercore, MD, Psychology, Silver Hill Hospital, Social anxiety disorder, Machine learning, Medical director, Yale University, Medicine, Nursing

Precision psychiatry startup Tetricus Labs has partnered with Silver Hill Hospital , one of the nation’s premier psychiatric hospitals, on a two-year feasibility study to assess how machine learning can significantly improve patient outcomes.

Key Points: 
  • Precision psychiatry startup Tetricus Labs has partnered with Silver Hill Hospital , one of the nation’s premier psychiatric hospitals, on a two-year feasibility study to assess how machine learning can significantly improve patient outcomes.
  • “We're patient-founded, patient-owned, and patient-run,” said Dow, CEO for Tetricus Labs.
  • Andrew J. Gerber, MD, PhD, President and Medical Director of Silver Hill Hospital, will join Tetricus Labs as a Medical Advisor to ensure Tetricus’ machine learning software is designed to fit within the busy workflow of hospital clinicians and staff, maximizing its accessibility for providers and potential impact on patient outcomes.
  • “This partnership represents our continued commitment to exploring innovative methods that can enhance our understanding of psychiatric disorders and improve patient outcomes."

Vistagen to Present at the 2024 Anxiety and Depression Association (ADAA) Conference

Retrieved on: 
Tuesday, April 9, 2024
Mental Health, Health, FDA, Clinical Trials, Pharmaceutical, Biotechnology, Conference, Depression, ADAA, Anxiety, Clinical trial, DSM-IV codes, Signs and symptoms, Premenstrual dysphoric disorder, Social anxiety disorder, Psychiatry, SAD, Publication

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it will present posters detailing clinical trial data for fasedienol, an investigational pherine candidate in Phase 3 development for the acute treatment of social anxiety disorder (SAD), and PH80, a Phase 2 investigational pherine candidate for treatment of women’s health disorders, at the Anxiety and Depression Association of America (ADAA) Conference in Boston, Massachusetts from April 11 to 14, 2024.

Key Points: 
  • Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver groundbreaking therapies for individuals affected by psychiatric and neurological disorders, today announced that it will present posters detailing clinical trial data for fasedienol, an investigational pherine candidate in Phase 3 development for the acute treatment of social anxiety disorder (SAD), and PH80, a Phase 2 investigational pherine candidate for treatment of women’s health disorders, at the Anxiety and Depression Association of America (ADAA) Conference in Boston, Massachusetts from April 11 to 14, 2024.
  • Title: PH80 Nasal Spray for Acute Management of the Symptoms of Premenstrual Dysphoric Disorder: Results from a Phase 2a Study
    The posters will be available on the Publications page of Vistagen’s website on Monday, April 15, 2024.
  • In addition to presenting fasedienol and PH80 clinical data, Vistagen will receive the ADAA 2024 Partner Recognition Award, recognizing Vistagen as a partner organization that has consistently contributed to the success of ADAA’s annual conference and supported ADAA’s public and professional mission.
  • Vistagen and ADAA are committed to redefining the future of mental health care and bringing hope to millions of individuals affected by debilitating mental health disorders.

Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting

Retrieved on: 
Thursday, March 21, 2024
MGH, Eating, Obesity, Oxytocin, Patient, Weight loss, Binge eating disorder, University, Prader–Willi syndrome, Tonix Pharmaceuticals, IND, American Chemical Society, Magnesium, Adolescence, Insulin resistance, Hospital, Safety, ACS, Social anxiety disorder, Spectrum, Pain, Nasal administration, Poster

CHATHAM, N.J., March 21, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announces a poster presentation at the American Chemistry Society (ACS) Spring 2024 Meeting, held March 17-21, 2024, in New Orleans, Louisiana. A copy of the poster is available under the scientific presentations page of the Tonix website at www.tonixpharma.com.

Key Points: 
  • A copy of the poster is available under the scientific presentations page of the Tonix website at www.tonixpharma.com .
  • The poster presentation titled, Oxytocin Analogs with Enhanced Craniofacial Antinociceptive Effects in Low Magnesium Formulations, describes the discovery and characterization of novel oxytocin analogues that are candidate treatments for craniofacial pain, excessive eating (including Prader Willi Syndrome), and endocrinological conditions including bone health in autism and insulin resistance.
  • “Intranasal oxytocin has several potential therapeutic applications,” said Seth Lederman, M.D., Chief Executive Officer of Tonix Pharmaceuticals.
  • The Phase 2 ‘STROBE’ study at MGH is investigating the efficacy and safety of TNX-1900 as a novel therapeutic agent to reduce binge eating frequency in adults with binge-eating disorder.

Vistagen Initiates PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder Following Positive Results of PALISADE-2

Retrieved on: 
Monday, April 1, 2024
Mental Health, Health, Neurology, Clinical Trials, Pharmaceutical, Biotechnology, SUDS, Social anxiety disorder, Psychiatry, Patient, Anxiety, SAD, DSM-IV codes, Safety, Nursing

“Initiating PALISADE-3 is another major milestone in our plan to develop and commercialize fasedienol as the first treatment of its kind for social anxiety disorder,” said Shawn Singh, Chief Executive Officer.

Key Points: 
  • “Initiating PALISADE-3 is another major milestone in our plan to develop and commercialize fasedienol as the first treatment of its kind for social anxiety disorder,” said Shawn Singh, Chief Executive Officer.
  • The U.S. multi-center study is planned to randomize approximately 236 adults ages 18 through 65.
  • Patients will be randomized in a 1:1 ratio to fasedienol or placebo.
  • Vistagen plans to initiate PALISADE-4, which will be a replicate of PALISADE-3, during the second half of 2024.

Bionomics to Present at the 2024 BIO CEO & Investor Conference

Retrieved on: 
Thursday, February 22, 2024
Social anxiety disorder, Central nervous system, Bionomics, BIO, Conference, CNS, Patient, BNC210

ADELAIDE, Australia and CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will be presenting at the 2024 BIO CEO & Investor Conference taking place February 26-27, 2024 in New York, NY.

Key Points: 
  • ADELAIDE, Australia and CAMBRIDGE, Mass., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today announced that it will be presenting at the 2024 BIO CEO & Investor Conference taking place February 26-27, 2024 in New York, NY.
  • Spyros Papapetropoulos, M.D., Ph.D., President and CEO of Bionomics will be providing an update on the Company’s leading asset, BNC210, a Phase 3 ready, first- and best-in-class α7 nicotinic receptor negative allosteric modulator in development for the treatment of social anxiety disorder and post-traumatic stress disorder.
  • For those interested in meeting Bionomics’ management during the conference, please request a meeting through the conference portal or contact the Company’s Investor Relations.
  • FOR FURTHER INFORMATION PLEASE CONTACT:

MycoMeditations Surveys Show Lasting Benefits of Psilocybin Therapy for Major Depression and Anxiety Disorders

Retrieved on: 
Tuesday, February 20, 2024
Psilocybin, GAD-7, Social anxiety, SAD, Mental health, Multimedia, PHQ-9, Treatment, Post-traumatic stress disorder, GAD, Anxiety, Generalized anxiety disorder, Social anxiety disorder, Major depressive disorder, Clinical trial, PTSD, MDD, Comment, Research

TREASURE BEACH, Jamaica, Feb. 20, 2024 /PRNewswire-PRWeb/ -- MycoMeditations, a pioneer in legal psilocybin-assisted therapy retreats, today announced the results of two years of longitudinal (long-term) client surveys exploring the impact of its psilocybin retreats on individuals suffering with Major Depressive Disorder (MDD), Generalized Anxiety Disorder (GAD), and Social Anxiety Disorder (SAD). The findings complement MycoMeditations' previously released surveys focused on Post-Traumatic Stress Disorder (PTSD).

Key Points: 
  • The findings complement MycoMeditations' previously released surveys focused on Post-Traumatic Stress Disorder (PTSD).
  • MycoMeditations employed the PHQ-9, GAD-7, and SM-SAD-Adult questionnaires to measure self-reported symptom severity and long-term outcomes across MDD, GAD, and SAD, respectively.
  • Clinically significant improvements were maintained for one year following retreat for each Major Depressive Disorder, Generalized Anxiety, and Social Anxiety, suggesting possible long-term efficacy of psilocybin-assisted therapy.
  • The data suggests the viability of multiple psilocybin treatments in a short period of time when coupled with therapy, as MycoMeditations retreats are 7-nights with 3 psilocybin sessions on alternating days.

Vistagen Reports Fiscal 2024 Third Quarter Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, February 13, 2024
Mental Health, Research, Neurology, Clinical Trials, Biotechnology, Health, Pharmaceutical, General Health, Science, Momentum, Social anxiety disorder, Anxiety, SAD, Premenstrual dysphoric disorder, Psychiatry, Safety, Menopause, SUDS, Patient, DSM-IV codes, G&A, MDD, PMDD, NDA, Hot, Pharmaceutical industry

Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today reported financial results for its fiscal year 2024 third quarter ended December 31, 2023 and provided a corporate update.

Key Points: 
  • Vistagen (Nasdaq: VTGN), a late clinical-stage biopharmaceutical company pioneering neuroscience to deliver first-in-class therapies for psychiatric and neurological disorders, today reported financial results for its fiscal year 2024 third quarter ended December 31, 2023 and provided a corporate update.
  • As of February 12, 2024, the Company had 27,029,731 shares of common stock issued and 3,577,240 pre-funded warrants outstanding.
  • Vistagen will host a conference call and live audio webcast this afternoon at 5:00 p.m. Eastern Time to provide a corporate update.
  • In addition, a telephone playback of the call will be available after approximately 8:00 p.m. Eastern Time on Tuesday, February 13, 2024.

Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Distribution Channel; and By Region - ResearchAndMarkets.com

Retrieved on: 
Thursday, February 8, 2024
Pharmaceutical, Health, Mental Health, Internet, Anxiety, DSM-IV codes, SAD, MDD, Research, PureTech Health, USD, Pharmacy, Social anxiety disorder, Prevalence, Patient, Distribution, GAD, PH94B, Ulotaront, FDA, Disorder, Tic disorder, PPD, Market, Depression, AbbVie, Zuranolone, MOA, Food, Commercialization, Therapy, TAAR1, Major depressive disorder, Sunovion, ADAA, Postpartum depression, NDA, Biogen, Conference, Pharmaceutical industry

The "Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Distribution Channel; and By Region" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Anxiety Disorders And Depression Treatment Market Analysis & Forecast 2024-2034: Market By Drug Class; By Indication; By Distribution Channel; and By Region" report has been added to ResearchAndMarkets.com's offering.
  • The global anxiety disorders and depression treatment market size was estimated to be USD 21.56 billion in 2023 and is expected to reach at USD 41.83 billion by 2034 with a CAGR of 6.21% during the forecast period 2024-2034.
  • Rising research & development activities for the development of innovative drugs for the treatment of anxiety & depression disorders is predicted to boost the market growth during the forecast period.
  • This application pertains to the use of cariprazine as an add-on treatment for individuals with major depressive disorder (MDD) who are already undergoing antidepressant therapy.

Bionomics Provides a Review of 2023 and of 2024 Plans

Retrieved on: 
Monday, January 22, 2024
MSD, Schizophrenia, BNC210, Deficit spending, Patient, Module (mathematics), PAMS, PTSD, Post-traumatic stress disorder, Sleep, Partnership, Merck & Co., GAD, NAM, Anxiety, Neuropsychiatry, SAD, Alzheimer's disease, Central nervous system, Australian Securities Exchange, FDA, DSM-IV codes, CIAS, Breakthrough therapy, Panic, Merck, Phase, Data analysis, Data, CNS, Social anxiety disorder, Pharmaceutical industry

ADELAIDE, Australia and CAMBRIDGE, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today provided a 2023 review and its outlook for 2024.

Key Points: 
  • ADELAIDE, Australia and CAMBRIDGE, Mass., Jan. 22, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (Bionomics or Company), a clinical-stage biotechnology company developing novel, first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (CNS) disorders with high unmet medical need, today provided a 2023 review and its outlook for 2024.
  • “Bionomics continued its evolution into a U.S.-focused, late-stage clinical company last year.
  • Voluntarily delisted from the Australian Stock Exchange in August 2023 and is currently solely listed on the NASDAQ Global Market.
  • Bionomics continues to plan the initiation of its first Phase 3 study of BNC210 in patients with SAD.